 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Antal Zemplenyi and Robert McQueen.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
3.967 |
|
|
|
-
Zemplenyi AT, Chen NC, Anderson KE, Adamson B, DiStefano MJ, Nair KV, McQueen RB. Key Considerations for Assessing Real-World Comparative Effectiveness in the Context of the Drug Price Negotiation Program: A Case Study of Pembrolizumab. Pharmacoeconomics. 2025 09; 43(9):1147-1160.
Score: 0.913
-
Zemplenyi A, Leonard J, Wright GC, DiStefano MJ, Nair K, Anderson KE, McQueen RB. Innovative Payment Models for Sickle-Cell Disease Gene Therapies in Medicaid: Leveraging Real-World Data and Insights from CMMI's Gene Therapy Access Model. Pharmacoeconomics. 2025 05; 43(5):583-594.
Score: 0.892
-
Zemplenyi A, Leonard J, DiStefano MJ, Anderson KE, Wright GC, Mendola ND, Nair K, McQueen RB. Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid. Pharmacoeconomics. 2024 03; 42(3):319-328.
Score: 0.818
-
Zemplenyi AT, McQueen RB, Gyamfi HG, Paratane D, DiStefano MJ. Does conventional cost-effectiveness analysis disadvantage treatments for severe disease? Evidence from U.S. value assessments. Value Health. 2026 Sep 08.
Score: 0.248
-
DiStefano MJ, McQueen RB, Zheng H, Gyamfi HG, Ameyaw D, Campbell JD, Zemplenyi A. Opportunities for CMS to Further Specify and Broaden Its Approach to Assessing Unmet Medical Need in the Context of the Medicare Drug Price Negotiation Program. Appl Health Econ Health Policy. 2026 03; 24(2):261-269.
Score: 0.233
-
DiStefano MJ, Zemplenyi A, Anderson KE, Mendola ND, Nair KV, McQueen RB. Alternative approaches to measuring value: an update on innovative methods in the context of the United States Medicare drug price negotiation program. Expert Rev Pharmacoecon Outcomes Res. 2024 Feb; 24(2):171-180.
Score: 0.207
-
DiStefano MJ, Zemplenyi A, McQueen RB. Assessing clinical benefit in the Medicare Drug Price Negotiation Program: A 2-step approach for improving transparency, consistency, and meaningful patient engagement. J Manag Care Spec Pharm. 2024 Mar 01; 30(3):252-258.
Score: 0.207
-
McQueen RB, Inotai A, Zemplenyi A, Mendola N, Németh B, Kalo Z. Multistakeholder Perceptions of Additional Value Elements for United States Value Assessment of Health Interventions. Value Health. 2024 01; 27(1):15-25.
Score: 0.203
-
McKenna A, Rind DM, McQueen RB, Zemplenyi A, Prosser LA, Richardson M, Cassim S, Phillips M, Gyimah Gyamfi H, Ollendorf DA. Vaccines for COVID-19: Effectiveness and value. J Manag Care Spec Pharm. 2026 Oct; 32(10):1313-1318.
Score: 0.062
-
Dardouri M, Zemplenyi A, Mendola ND, McQueen RB, Anderson HD, Anderson KE. Dissertation Topic Selection Priorities Among Pharmaceutical Outcomes Research Students and Alumni. Am J Pharm Educ. 2026 Aug 22; 90(11):102071.
Score: 0.062
-
McKenna A, Wasfy JH, McQueen RB, Cassim S, DiStefano MJ, Zemplenyi A, Lee W, Phillips M, Paratane D, Rind DM, Agboola F. The effectiveness and value of B-cell-directed therapies for the treatment of immunoglobulin A nephropathy. J Manag Care Spec Pharm. 2026 Jul; 32(7):878-884.
Score: 0.061
-
Chen NC, Zemplenyi AT, Adamson B, Kaizer AM, O'Bryant CL, McQueen RB, Anderson KE. Using Regression Discontinuity in Time to Strengthen Real-World Evidence: A Case Study in Lung Cancer. Med Decis Making. 2026 Jul; 46(5):601-623.
Score: 0.060
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|